摘要
近五年相继提出了原发性骨髓纤维化（PMF）的骨髓纤维化程度判断欧洲共识标准、国际预后积分系统（IPSS）和疗效标准,为PMF的规范化诊断和治疗奠定了基础.免疫调节剂如沙利度胺、雷利度胺和pomalidomide单独或联合小剂量泼尼松临床试验的完成,使得除造血干细胞移植以外的药物治疗逆转骨髓纤维化程度成为可能,新近JAK2抑制剂临床试验的开展使PMF进入分子靶向治疗新时代.文章结合国际上PMF研究的新认识,重点探讨了中国在该领域应引起重视的几个问题.
During the past few years, European consensus on grading bone marrow fibrosis, the Dynamic International Prognostic Scoring System （DIPSS） for primary myelofibrosis（PMF） and response criteria for PMF were developed, and some new drugs, such as the immunomodulator drugs （IMiDs） and JAK2 inhibitor are available for PMF. The recent advances were summarized and future issues were discussed.
出处
《白血病．淋巴瘤》
CAS
2010年第9期513-516,522,共5页
Journal of Leukemia & Lymphoma
基金
卫生行业科研专项经费项目（2010）
关键词
原发性骨髓纤维化
诊断
治疗
预后
Primary myelofibrosis
Diagnosis
Treatment
Prognosis
